ReShape Lifesciences Files S-1/A Update

Ticker: HIND · Form: S-1/A · Filed: Feb 6, 2025 · CIK: 1427570

Reshape Lifesciences Inc. S-1/A Filing Summary
FieldDetail
CompanyReshape Lifesciences Inc. (HIND)
Form TypeS-1/A
Filed DateFeb 6, 2025
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $3.77, $0, $3.57, $1.15 million
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, s-1/a, securities

TL;DR

ReShape Lifesciences filed an S-1/A update on Feb 6, 2025, related to warrants and financial reporting.

AI Summary

ReShape Lifesciences Inc. filed an S-1/A on February 6, 2025, to update its registration statement. The company, formerly Obalon Therapeutics Inc., is based in San Clemente, CA, and operates in the Pharmaceutical Preparations sector. This filing relates to securities, including warrants, and financial reporting metrics such as impairment of intangible assets and fair value adjustments.

Why It Matters

This S-1/A filing indicates ongoing regulatory and financial activities for ReShape Lifesciences, potentially impacting investors and stakeholders regarding the company's securities and financial health.

Risk Assessment

Risk Level: medium — S-1/A filings often relate to securities offerings or significant financial updates, which can carry inherent investment risks.

Key Numbers

  • 1001 CALLE AMANECER — Business Address (Headquarters of ReShape Lifesciences Inc.)
  • 949-429-6680 — Business Phone (Contact number for ReShape Lifesciences Inc.)

Key Players & Entities

  • ReShape Lifesciences Inc. (company) — Filer of the S-1/A
  • Obalon Therapeutics Inc. (company) — Former name of ReShape Lifesciences Inc.
  • 20250206 (date) — Filing date of the S-1/A
  • 333-284362 (dollar_amount) — SEC file number
  • 25595382 (dollar_amount) — Film number

FAQ

What is the primary purpose of this S-1/A filing for ReShape Lifesciences Inc.?

The S-1/A filing is an amendment to a registration statement, indicating updates or changes to previously filed information concerning the company's securities and financial status.

When was this S-1/A filing submitted?

The filing was submitted on February 6, 2025.

What was ReShape Lifesciences Inc. formerly known as?

ReShape Lifesciences Inc. was formerly known as Obalon Therapeutics Inc.

What industry sector does ReShape Lifesciences Inc. operate in?

ReShape Lifesciences Inc. operates in the Pharmaceutical Preparations sector, with SIC code 2834.

What specific financial concepts are mentioned in relation to this filing?

The filing mentions concepts such as ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill and FairValueAdjustmentOfWarrants, along with inputs for the Black-Scholes model used in valuing warrants.

Filing Stats: 4,554 words · 18 min read · ~15 pages · Grade level 14.9 · Accepted 2025-02-06 06:46:17

Key Financial Figures

  • $0.001 — ne share of our common stock, par value $0.001 per share (the "Common Stock" or "commo
  • $3.77 — at an assumed public offering price of $3.77 per Unit, based upon the closing price
  • $0 — luding one share of Common Stock, minus $0.001, and the remaining exercise price o
  • $3.57 — orted on the Nasdaq Capital Market, was $3.57 per share. There is no established trad
  • $1.15 million — development has received approximately $1.15 million dollars of nondilutive NIH grant suppor
  • $5,000,000 — tal maximum aggregate purchase price of $5,000,000 (the "Purchase Shares"), upon the terms
  • $833,333.34 — aggregate original principal amount of $833,333.34 (the "Note"), and also issued to Ascent
  • $45,000 — ings from 66% to 50%, and (d) require a $45,000 cash extension fee to be paid by the Co

Filing Documents

RISK FACTORS

RISK FACTORS 11 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 49 CAPITALIZATION 50

USE OF PROCEEDS

USE OF PROCEEDS 52 MARKET AND DIVIDEND INFORMATION FOR OUR COMMON STOCK 53

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 91

BUSINESS

BUSINESS 67 EXECUTIVE AND DIRECTOR COMPENSATION 88 MANAGEMENT 91

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 98 DESCRIPTION OF EQUITY FINANCING TRANSACTION 99 DESCRIPTION OF CONVERTIBLE NOTE TRANSACTION 101

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 102

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 106 MATERIAL U.S. FEDERAL TAX CONSIDERATIONS FOR HOLDERS OF COMMON STOCK 110 PLAN OF DISTRIBUTION 116 RESHAPE AND VYOME UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS 122 VYOME INFORMATION 134 LEGAL MATTERS 226 EXPERTS 226 WHERE YOU CAN FIND MORE INFORMATION 226 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY 226 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 for the offering by us of shares of common stock. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or our securities registered under the registration statement of which this prospectus forms a part are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus in making your investment decision. You should also read and consider the information in the documents to which we have referred you under the captions " Where You Can Find Additional Information " in this prospectus. Neither we nor the placement agent have authorized anyone to provide any information or to make any representation other than those contained in this prospectus. You must not rely upon any information or representation not contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our securities other than the securities covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy any securities of our company in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such juri

View Full Filing

View this S-1/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.